New drug shows promise for hospitalized heart failure patients
NCT ID NCT06556810
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This early-stage trial tests a drug called atibuclimab (IC14) in 10 adults hospitalized with acute decompensated heart failure. The main goals are to check if the drug is safe and how it affects heart failure markers. Participants receive one IV dose and are followed for 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.